98%
921
2 minutes
20
High endothelial venules (HEV) are specialized post capillary venules that recruit naïve T cells and B cells into secondary lymphoid organs (SLO) such as lymph nodes (LN). Expansion of HEV networks in SLOs occurs following immune activation to support development of an effective immune response. In this study, we used a carcinogen-induced model of fibrosarcoma to examine HEV remodeling after depletion of regulatory T cells (Treg). We used light sheet fluorescence microscopy imaging to visualize entire HEV networks, subsequently applying computational tools to enable topological mapping and extraction of numerical descriptors of the networks. While these analyses revealed profound cancer- and immune-driven alterations to HEV networks within LNs, these changes did not identify successful responses to treatment. The presence of HEV networks within tumors did however clearly distinguish responders from nonresponders. Finally, we show that a successful treatment response is dependent on coupling tumor-associated HEV (TA-HEV) development to T-cell activation implying that T-cell activation acts as the trigger for development of TA-HEVs which subsequently serve to amplify the immune response by facilitating extravasation of T cells into the tumor mass.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614106 | PMC |
http://dx.doi.org/10.1158/2767-9764.CRC-21-0123 | DOI Listing |
mSystems
August 2025
Virology Laboratory, Center for Virus research, therapeutics and vaccines, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis in lower- and middle-income countries. HEV infection may lead to acute liver failure, chronic liver disease, and high mortality in pregnant women. Antiviral therapy is not a standard treatment for HEV patients.
View Article and Find Full Text PDFVet Res Commun
July 2025
School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Hepatitis E virus (HEV) is widely recognized as an emerging public health issue in developed countries, with most infections linked to foodborne transmission of genotype HEV-3. This zoonotic genotype can infect a diverse range of mammalian species, including bovine, with pigs serving as the primary reservoir. The aim of the present study was to investigate the occurrence, circulation, and the potential of HEV infection among bovines in Portugal.
View Article and Find Full Text PDFComput Biol Med
September 2025
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA; USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Electronic address:
There are five different types of the hepatotropic hepatitis viruses (HAV, HBV, HCV, HDV, and HEV). Infection with all hepatitis viruses leads to the development of disease, and all of them are capable of co-infection and super-infection; i.e.
View Article and Find Full Text PDFHigh endothelial cells (HECs) and intestinal goblet cells (GCs) are highly specialized through organelle expansion and metabolism for production of sulfated mucins essential for lymphocyte homing and mucosal defense, respectively. How these cells coordinate organelle architecture and biosynthetic pathways to support such demands remains poorly understood. Here, we show at single-cell resolution that HECs rely on gene regulatory networks driven by IRE1α-XBP1 and CREB3L1/2 transcription factors.
View Article and Find Full Text PDFNat Struct Mol Biol
July 2025
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.
Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses without approved human vaccines or therapies. Here, we report on a highly potent bispecific therapeutic that combines an anti-fusion glycoprotein nanobody with an anti-receptor-binding glycoprotein (RBP) antibody to deliver a dual-targeting biologic that is resistant to viral escape. We show that the nanobody, DS90, engages a unique, conserved site within the fusion glycoprotein of NiV and HeV and provides neutralization and complete protection from NiV disease.
View Article and Find Full Text PDF